In a report released yesterday, Ritu Baral from Cowen & Co. maintained a Buy rating on Aptinyx Inc (APTX). The company’s shares closed yesterday at $3.73, close to its 52-week low of $3.45.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 27.0% and a 52.4% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.
Currently, the analyst consensus on Aptinyx Inc is a Strong Buy with an average price target of $13.50, a 261.9% upside from current levels. In a report issued on April 30, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $12 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $32.25 and a one-year low of $3.45. Currently, Aptinyx Inc has an average volume of 382.3K.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of APTX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aptinyx Inc. is a clinical stage biopharmaceutical company. It engages in the discovery, development, and and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program.
